Advanced Cell plunges on stock sales fraud charges
This article was originally published in Scrip
Executive Summary
Shares of Advanced Cell Technology (ACT) plunged 13.3% on 10 September after the Securities and Exchange Commission (SEC) charged the Massachusetts-based biotech and its former CEO Gary Rabin with defrauding investors by failing to report insider sales of company's stock.